The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugate Market Research Report 2025
Synopsis
The global Antibody Drug Conjugate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate.
Report Scope
The Antibody Drug Conjugate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
Segment by Type
Adcetris
Kadcyl
Other
Segment by Application
Hospital
Pharmaceutical Company
Research Institutions
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibody Drug Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibody Drug Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Antibody Drug Conjugate market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate.
Report Scope
The Antibody Drug Conjugate market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Seattle Genetics/Takeda
Roche
ImmunoGen
Immunomedics
Pfizer
Celldex Therapeutics
Millennium Pharmaceuticals
Bayer HealthCare
Mersana Therapeutics
Heidelberg Pharma
Oxford BioTherapeutics
Takeda Pharmaceutical Company Limited
Segment by Type
Adcetris
Kadcyl
Other
Segment by Application
Hospital
Pharmaceutical Company
Research Institutions
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Antibody Drug Conjugate manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Antibody Drug Conjugate in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Antibody Drug Conjugate Market Overview
1.1 Product Overview and Scope of Antibody Drug Conjugate
1.2 Antibody Drug Conjugate Segment by Type
1.2.1 Global Antibody Drug Conjugate Market Value Comparison by Type (2024-2030)
1.2.2 Adcetris
1.2.3 Kadcyl
1.2.4 Other
1.3 Antibody Drug Conjugate Segment by Application
1.3.1 Global Antibody Drug Conjugate Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Pharmaceutical Company
1.3.4 Research Institutions
1.4 Global Antibody Drug Conjugate Market Size Estimates and Forecasts
1.4.1 Global Antibody Drug Conjugate Revenue 2019-2030
1.4.2 Global Antibody Drug Conjugate Sales 2019-2030
1.4.3 Global Antibody Drug Conjugate Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Antibody Drug Conjugate Market Competition by Manufacturers
2.1 Global Antibody Drug Conjugate Sales Market Share by Manufacturers (2019-2024)
2.2 Global Antibody Drug Conjugate Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Antibody Drug Conjugate Average Price by Manufacturers (2019-2024)
2.4 Global Antibody Drug Conjugate Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Antibody Drug Conjugate, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antibody Drug Conjugate, Product Type & Application
2.7 Antibody Drug Conjugate Market Competitive Situation and Trends
2.7.1 Antibody Drug Conjugate Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antibody Drug Conjugate Players Market Share by Revenue
2.7.3 Global Antibody Drug Conjugate Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antibody Drug Conjugate Retrospective Market Scenario by Region
3.1 Global Antibody Drug Conjugate Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Antibody Drug Conjugate Global Antibody Drug Conjugate Sales by Region: 2019-2030
3.2.1 Global Antibody Drug Conjugate Sales by Region: 2019-2024
3.2.2 Global Antibody Drug Conjugate Sales by Region: 2025-2030
3.3 Global Antibody Drug Conjugate Global Antibody Drug Conjugate Revenue by Region: 2019-2030
3.3.1 Global Antibody Drug Conjugate Revenue by Region: 2019-2024
3.3.2 Global Antibody Drug Conjugate Revenue by Region: 2025-2030
3.4 North America Antibody Drug Conjugate Market Facts & Figures by Country
3.4.1 North America Antibody Drug Conjugate Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Antibody Drug Conjugate Sales by Country (2019-2030)
3.4.3 North America Antibody Drug Conjugate Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Antibody Drug Conjugate Market Facts & Figures by Country
3.5.1 Europe Antibody Drug Conjugate Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Antibody Drug Conjugate Sales by Country (2019-2030)
3.5.3 Europe Antibody Drug Conjugate Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibody Drug Conjugate Market Facts & Figures by Country
3.6.1 Asia Pacific Antibody Drug Conjugate Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Antibody Drug Conjugate Sales by Country (2019-2030)
3.6.3 Asia Pacific Antibody Drug Conjugate Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antibody Drug Conjugate Market Facts & Figures by Country
3.7.1 Latin America Antibody Drug Conjugate Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Antibody Drug Conjugate Sales by Country (2019-2030)
3.7.3 Latin America Antibody Drug Conjugate Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antibody Drug Conjugate Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibody Drug Conjugate Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Antibody Drug Conjugate Sales by Country (2019-2030)
3.8.3 Middle East and Africa Antibody Drug Conjugate Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antibody Drug Conjugate Sales by Type (2019-2030)
4.1.1 Global Antibody Drug Conjugate Sales by Type (2019-2024)
4.1.2 Global Antibody Drug Conjugate Sales by Type (2025-2030)
4.1.3 Global Antibody Drug Conjugate Sales Market Share by Type (2019-2030)
4.2 Global Antibody Drug Conjugate Revenue by Type (2019-2030)
4.2.1 Global Antibody Drug Conjugate Revenue by Type (2019-2024)
4.2.2 Global Antibody Drug Conjugate Revenue by Type (2025-2030)
4.2.3 Global Antibody Drug Conjugate Revenue Market Share by Type (2019-2030)
4.3 Global Antibody Drug Conjugate Price by Type (2019-2030)
5 Segment by Application
5.1 Global Antibody Drug Conjugate Sales by Application (2019-2030)
5.1.1 Global Antibody Drug Conjugate Sales by Application (2019-2024)
5.1.2 Global Antibody Drug Conjugate Sales by Application (2025-2030)
5.1.3 Global Antibody Drug Conjugate Sales Market Share by Application (2019-2030)
5.2 Global Antibody Drug Conjugate Revenue by Application (2019-2030)
5.2.1 Global Antibody Drug Conjugate Revenue by Application (2019-2024)
5.2.2 Global Antibody Drug Conjugate Revenue by Application (2025-2030)
5.2.3 Global Antibody Drug Conjugate Revenue Market Share by Application (2019-2030)
5.3 Global Antibody Drug Conjugate Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Seattle Genetics/Takeda
6.1.1 Seattle Genetics/Takeda Corporation Information
6.1.2 Seattle Genetics/Takeda Description and Business Overview
6.1.3 Seattle Genetics/Takeda Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Seattle Genetics/Takeda Antibody Drug Conjugate Product Portfolio
6.1.5 Seattle Genetics/Takeda Recent Developments/Updates
6.2 Roche
6.2.1 Roche Corporation Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Roche Antibody Drug Conjugate Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 ImmunoGen
6.3.1 ImmunoGen Corporation Information
6.3.2 ImmunoGen Description and Business Overview
6.3.3 ImmunoGen Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.3.4 ImmunoGen Antibody Drug Conjugate Product Portfolio
6.3.5 ImmunoGen Recent Developments/Updates
6.4 Immunomedics
6.4.1 Immunomedics Corporation Information
6.4.2 Immunomedics Description and Business Overview
6.4.3 Immunomedics Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Immunomedics Antibody Drug Conjugate Product Portfolio
6.4.5 Immunomedics Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Pfizer Antibody Drug Conjugate Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Celldex Therapeutics
6.6.1 Celldex Therapeutics Corporation Information
6.6.2 Celldex Therapeutics Description and Business Overview
6.6.3 Celldex Therapeutics Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Celldex Therapeutics Antibody Drug Conjugate Product Portfolio
6.6.5 Celldex Therapeutics Recent Developments/Updates
6.7 Millennium Pharmaceuticals
6.6.1 Millennium Pharmaceuticals Corporation Information
6.6.2 Millennium Pharmaceuticals Description and Business Overview
6.6.3 Millennium Pharmaceuticals Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Millennium Pharmaceuticals Antibody Drug Conjugate Product Portfolio
6.7.5 Millennium Pharmaceuticals Recent Developments/Updates
6.8 Bayer HealthCare
6.8.1 Bayer HealthCare Corporation Information
6.8.2 Bayer HealthCare Description and Business Overview
6.8.3 Bayer HealthCare Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Bayer HealthCare Antibody Drug Conjugate Product Portfolio
6.8.5 Bayer HealthCare Recent Developments/Updates
6.9 Mersana Therapeutics
6.9.1 Mersana Therapeutics Corporation Information
6.9.2 Mersana Therapeutics Description and Business Overview
6.9.3 Mersana Therapeutics Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Mersana Therapeutics Antibody Drug Conjugate Product Portfolio
6.9.5 Mersana Therapeutics Recent Developments/Updates
6.10 Heidelberg Pharma
6.10.1 Heidelberg Pharma Corporation Information
6.10.2 Heidelberg Pharma Description and Business Overview
6.10.3 Heidelberg Pharma Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Heidelberg Pharma Antibody Drug Conjugate Product Portfolio
6.10.5 Heidelberg Pharma Recent Developments/Updates
6.11 Oxford BioTherapeutics
6.11.1 Oxford BioTherapeutics Corporation Information
6.11.2 Oxford BioTherapeutics Antibody Drug Conjugate Description and Business Overview
6.11.3 Oxford BioTherapeutics Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Oxford BioTherapeutics Antibody Drug Conjugate Product Portfolio
6.11.5 Oxford BioTherapeutics Recent Developments/Updates
6.12 Takeda Pharmaceutical Company Limited
6.12.1 Takeda Pharmaceutical Company Limited Corporation Information
6.12.2 Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Description and Business Overview
6.12.3 Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Takeda Pharmaceutical Company Limited Antibody Drug Conjugate Product Portfolio
6.12.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibody Drug Conjugate Industry Chain Analysis
7.2 Antibody Drug Conjugate Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibody Drug Conjugate Production Mode & Process
7.4 Antibody Drug Conjugate Sales and Marketing
7.4.1 Antibody Drug Conjugate Sales Channels
7.4.2 Antibody Drug Conjugate Distributors
7.5 Antibody Drug Conjugate Customers
8 Antibody Drug Conjugate Market Dynamics
8.1 Antibody Drug Conjugate Industry Trends
8.2 Antibody Drug Conjugate Market Drivers
8.3 Antibody Drug Conjugate Market Challenges
8.4 Antibody Drug Conjugate Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
